摘要
目的探讨支气管哮喘患儿慢性持续期药物治疗前后肺功能、三种细胞数量和炎性标志物水平的临床意义。方法肺功能、细胞免疫功能和炎性标志物水平分析了356例哮喘患儿(包括213例临床控制组、63例显效组、49例有效组和31例无效组)药物治疗前后的变化,并进行了对比性研究。结果通过药物治疗,临床控制组、显效组、有效组肺功能:第1秒用力呼气容积(FEV1)、最大呼气峰流速(PEF)和FEV1/用力肺活量比值(FEV1/FVC)水平治疗后较治疗前明显增高,三种细胞数量[WBC,中性粒细胞(N)和嗜酸性粒细胞(EOS)]水平治疗后较治疗前明显降低,无效组无明显改变;上述前三组细胞免疫功能明显降低,无效组亦无明显差异;炎性标志物中三组血清25羟基维生素D[25(OH)D]和白介素10(IL-10)水平明显增高,血清降钙素原(PCT)和纤维蛋白原(FIB)水平治疗后较治疗前明显降低。无效组无明显差异,药物治疗的总有效率为91.29%。结论血清炎性标志物水平是哮喘患儿慢性持续期药物治疗前后评估的最佳指标之一。
Objective To conduct a clinical study of lung function,three different cell counts and inflammatory markers in chronic duration before and after drug treatments in pediatric patients with asthma.Methods A total of 356 pediatric patients with asthma(including groups of 213 cases of clinical control,63 cases with obvious effect and 49 cases with effect and 31 cases with no effect)were analyzed before and after drug treatments through lung functions,cell immunofunction and inflammatory markers,and results were compared.Results Our results of before and after drug treatments showed as following:the lung function(FEV1、PEF和FEV1/FVC)levels of groups of clinical control,obvious effect and effect were significantly increased,while the cell immunofunction(WBC,N and EOS)levels of these three groups were significantly decreased,the group of no effect had no obvious changes.For inflammatory makers of these three groups,the serum 25(OH)D and IL-10 levels were significantly increased,while the serum PCT and FIB levels were significantly decreased and the no effect group showed no significant difference.The total effect ratio was 91.29%.Conclusion The serum inflammatory markers can be used as indexes for predicting chronic duration of pediatric asthma before and after drug treatments.
作者
朱颋
陈颖
吴萍
ZHU Ting;CHEN Ying;WU Ping(Department of Pediatrics,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou 215002,China)
出处
《标记免疫分析与临床》
CAS
2021年第1期32-36,共5页
Labeled Immunoassays and Clinical Medicine
基金
2018年苏州市科技发展计划项目(编号:SYSD2018129)。
